MitoChem has developed a new class of small molecules designed to treat mitochondrial dysfunction, a hallmark mechanism of aging and metabolic diseases. Mitochondrial dysfunction creates a metabolic crisis in cells and is implicated in the underlying pathological basis in neurodegeneration (Alzheimer’s, Parkinson’s, ALS, retinal degeneration…), metabolic diseases (diabetes, NASH, NAFLD…) and ischemia reperfusion injury (stroke, acute kidney injury, myocardial infarction,…). Funding of $4.1m from foundations, NIH, founders and management have resulted in a robust patent portfolio, favorable early tox data and a lead compound with proof of concept in numerous animal models for rare and large challenging diseases. The lead program is a rare eye disease, retinitis pigmentosa, for which FDA has granted the company Orphan Drug Designation. The company is pursuing institutional investment and partnerships to advance current development programs in the eye and kidney as well as other neurodegeneration indications.
Focus Areas
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
